Wolfson, J. A., Grimes, A. C., Nuño, M. M., Ramakrishnan, S., Dickens, D. S., Roth, M. E., Woods, W., Adams, K. S., Alabi, T., Beauchemin, M., Levine, J. M., Scialla, M., Boayue, K. B., Kerber, C. L., Ponce, O., Vargas, S., Chang, G. J., Stock, W., Hershman, D., … Parsons, S. K. (2025). Guideline-concordant treatment among adolescents and young adults with acute lymphoblastic leukemia. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkaf033

Bertulfo, K., Perez-Duran, P., Miller, H., Ma, C., Ambesi-Impiombato, A., Samon, J., Mackey, A., Lin, W.-H. W., Ferrando, A. A., & Palomero, T. (2025). Therapeutic targeting of the NOTCH1 and neddylation pathways in T cell acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences, 122(14). https://doi.org/10.1073/pnas.2426742122

Frigault, M. J., Maziarz, R. T., Park, J. H., Lazaryan, A., Shah, N. N., Svoboda, J., Lekakis, L. J., Reshef, R., Phillips, C. L., Burke, L., Lei, J., Pratta, M., Morariu-Zamfir, R., & DiPersio, J. F. (2025). Itacitinib for the Prevention of IEC Therapy-Associated CRS: Results From the Two-Part Phase 2 INCB 39110-211 Study. Blood Journal. https://doi.org/10.1182/blood.2024026586

Shah, N. N., Schafer, E. S., Chi, Y., Malvar, J., Heym, K. M., Place, A. E., Burns, M., Chang, B. H., Slone, T., Verma, A., Gossai, N., Shaw, P. H., Burke, M. J., Hermiston, M., Schore, R. J., Cooper, T., Pauly, M., Rushing, T., Jarosinski, P., … Wayne, A. S. (2025). Vincristine Sulfate Liposome Injection with Combination Chemotherapy for Children, Adolescents, and Young Adults with Relapsed Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium Trial. Pediatric Blood & Cancer. Portico. https://doi.org/10.1002/pbc.31584

Hughes, T. M., Shrivastava, N., Silverman, L. B., Frazier, A. L., Gupta, S., & Denburg, A. (2025). Forecasting Asparaginase Need and Cost for Childhood Cancer Using ACCESS FORxECAST. JCO Global Oncology, 11. https://doi.org/10.1200/go-24-00444

Pelland-Marcotte, M.-C., Belaktib, A., Droit, A., Remy, M. M., Clement, J. G., Bianco, S., Ma, Y., Liu, J., Herrmann, L., Raufaste-Cazavieille, V., Joly-Beauparlant, C., Mangnier, L., Leclercq, M., Sontag, T., Caron, M., St-Onge, P., Langlois, S., Koch, V., Flamand, Y., … Santiago, R. (2024). Molecular signatures associated with venous thromboembolism in children with acute lymphoblastic leukemia. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.12.007

Gui, G., Ravindra, N., Hegde, P. S., Andrew, G., Mukherjee, D., Wong, Z., Auletta, J. J., El Chaer, F., Chen, E. C., Chen, Y.-B., Corner, A., Devine, S. M., Iyer, S. G., Jimenez Jimenez, A. M., De Lima, M. J. G., Litzow, M. R., Kebriaei, P., Saber, W., Spellman, S. R., … Hourigan, C. S. (2024). Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia. Bone Marrow Transplantation. https://doi.org/10.1038/s41409-024-02447-4

Maese, L. D., Loh, M. L., Choi, M. R., Agarwal, S., Aoki, E., Liang, Y., Lin, T., Girgis, S., Chen, C., Roller, S. G., Chandrasekaran, V., Iannone, R., Silverman, L. B., Raetz, E. A., & Rau, R. E. (2024). Recombinant Erwinia Asparaginase (JZP458) in ALL/LBL: Complete Follow-Up of the Children’s Oncology Group AALL1931 Study. Blood Advances. https://doi.org/10.1182/bloodadvances.2024013346

Torres-Diz, M., Reglero, C., Falkenstein, C. D., Castro, A., Hayer, K. E., Radens, C. M., Quesnel-Vallières, M., Ang, Z., Sehgal, P., Li, M. M., Barash, Y., Tasian, S. K., Ferrando, A., & Thomas-Tikhonenko, A. (2024). An Alternatively Spliced Gain-of-Function NT5C2 Isoform Contributes to Chemoresistance in Acute Lymphoblastic Leukemia. Cancer Research. https://doi.org/10.1158/0008-5472.can-23-3804

Vilarello, B. J., Jacobson, P. T., Gudis, D. A., & Overdevest, J. B. (2024). B-cell Lymphoblastic Lymphoma Presenting as a Sinonasal Mass: A Case Report. Cureus. https://doi.org/10.7759/cureus.58132

Brivio, E., Pennesi, E., Willemse, M. E., Huitema, A. D. R., Jiang, Y., van Tinteren, H. D. R., van der Velden, V. H. J., Beverloo, B. H., den Boer, M. L., Rammeloo, L. A. J., Hudson, C., Heerema, N., Kowalski, K., Zhao, H., Kuttschreuter, L., Bautista Sirvent, F. J., Bukowinski, A., Rizzari, C., Pollard, J., … Zwaan, C. M. (2024). Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921. Journal of Clinical Oncology, 42(7), 821–831. https://doi.org/10.1200/jco.23.00897

Lipsky, A. H., Hill, B. T., Winter, A., Bachow, S. H., Viny, A. D., Rosenblat, T. L., Jurcic, J., & Lamanna, N. (2023). Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL): High Rates of Undetectable Minimal Residual Disease Remissions. Blood, 142(Supplement 1), 3274–3274. https://doi.org/10.1182/blood-2023-189718

Garcia-Manero, G., Odenike, O., Fleming, S., Roboz, G. J., Jacoby, M., Cunningham, I., Kreuzer, K.-A., Enjeti, A. K., Baer, M. R., Cook, R., Jurcic, J., Ku, G., Zhou, Y., Hoffman, D., Potluri, J., & Garcia, J. S. (2023). Combination of Venetoclax and Azacitidine in Patients with Treatment-Naive, High-Risk Myelodysplastic Syndromes with Responses Leading to Stem Cell Transplantation. Blood, 142(Supplement 1), 1868–1868. https://doi.org/10.1182/blood-2023-187102

Chernak, B., Galan-Diez, M., Ali, A. M., Cuesta-Dominguez, A., Chen, Z., Koehnke, T., Majeti, R., Carroll, M., Raza, A., & Kousteni, S. (2023). Serum Amyloid A1 (SAA1) Secreted By the Stromal Microenvironment Drives Malignant Clonal Proliferation in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood, 142(Supplement 1), 4118–4118. https://doi.org/10.1182/blood-2023-174485

Al Malki, M. M., Keyzner, A., Suh, H. C., Matin, A., Buonomo, E., Wang, Y., Abelowitz, N., Murray, J., Macbeath, G., Barton, D., Chattopadhyay, S., & Reshef, R. (2023). Initial Results of a Phase 1 Trial of TSC-100 and TSC-101, Engineered T Cell Therapies That Target Minor Histocompatibility Antigens to Prevent Relapse after Allogeneic Hematopoietic Cell Transplantation. Blood, 142(Supplement 1), 2090–2090. https://doi.org/10.1182/blood-2023-187355

Barsan, V., Li, Y., Prabhu, S., Baggott, C., Nguyen, K., Pacenta, H., Phillips, C. L., Rossoff, J., Stefanski, H., Talano, J.-A., Moskop, A., Baumeister, S., Verneris, M. R., Myers, G. D., Karras, N. A., Cooper, S., Qayed, M., Hermiston, M., Satwani, P., … Schultz, L. M. (2023). Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns. EClinicalMedicine, 65, 102268. https://doi.org/10.1016/j.eclinm.2023.102268

Vásquez, L., Fuentes-Alabi, S., Benitez-Majano, S., Ribeiro, K. B., Abraham, M., Agulnik, A., Baker, J. N., Blanco, D. B., Caniza, M. A., Cardenas-Aguirre, A., Salaverria, C., Sullivan, C. E., Damasco-Avila, E., García-Quintero, X., Loggetto, P., McNeil, M. J., Luna-Fineman, S., Rossell, N., Garcia de Lima, R. A., … Maza, M. (2023). Collaboration for success: the Global Initiative for Childhood Cancer in Latin America. Revista Panamericana de Salud Pública, 47, 1. https://doi.org/10.26633/rpsp.2023.144

Schanberg, L. E., Mulugeta, L. (Yeruk), Akinlade, B., Brunner, H. I., Chen, J., Colbert, R. A., Delgaizo, V., Gastonguay, M. R., Glaser, R., Imundo, L., Lovell, D. J., Leu, J. H., Mostafa, N. M., Nelson, R. M., Nigrovic, P. A., Nikolov, N. P., Rider, L. G., Rothwell, R., Sahajwalla, C., … Yao, L. (2023). Therapeutic Development in Polyarticular Course Juvenile Idiopathic Arthritis: Extrapolation, Dose Selection, and Clinical Trial Design. Arthritis & Rheumatology, 75(10), 1856–1866. Portico. https://doi.org/10.1002/art.42534

Pratz, K. W., Cherry, M., Altman, J. K., Cooper, B. W., Podoltsev, N. A., Cruz, J. C., Lin, T. L., Schiller, G. J., Jurcic, J. G., Asch, A., Wu, R., Hill, J. E., Gill, S. C., James, A. J., Rich, E. S., Hasabou, N., Perl, A. E., & Levis, M. J. (2023). Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. Journal of Clinical Oncology, 41(26), 4236–4246. https://doi.org/10.1200/jco.22.02721

Akahoshi, Y., Spyrou, N., Hogan, W. J., Ayuk, F., DeFilipp, Z., Weber, D., Choe, H. K., Hexner, E. O., Rösler, W., Etra, A. M., Sandhu, K., Yanik, G. A., Chanswangphuwana, C., Kitko, C. L., Reshef, R., Kraus, S., Wölfl, M., Eder, M., Bertrand, H., … Chen, Y.-B. (2023). Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD. Blood Advances, 7(16), 4479–4491. https://doi.org/10.1182/bloodadvances.2023009885

Kater, A., Harrup, R., Kipps, T. J., Eichhorst, B., Owen, C. J., Assouline, S., Lamanna, N., Robak, T., de la Serna, J., Jaeger, U., Cartron, G., Montillo, M., Mellink, C., Chyla, B., Thadani-Mulero, M., Lefebure, M., Jiang, Y., Millen, R., Boyer, M., & Seymour, J. F. (2023). S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL). HemaSphere, 7(S3), e492813f. https://doi.org/10.1097/01.hs9.0000967716.49281.3f

Brivio, E., Pennesi, E., Willemse, M., Jiang, Y., van der Velden, V., Beverloo, B., Hudson, C., Kuttschreuter, L., van der Sluis, I., Brethon, B., Bautista, F., J. Burke, M., Heerema, N., Bukowinski, A., Cooper, S., Pollard, J., Nagasubramani, R., Redell, M., Bourquin, J.-P., … Zwaan, M. (2023). P676: UPDATED RESULTS FROM THE TRIAL ITCC-054/COG-AAML1921: BOSUTINIB IN NEWLY DIAGNOSED AND RESISTANT/INTOLERANT PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA. HemaSphere, 7(S3), e506783a. https://doi.org/10.1097/01.hs9.0000969608.50678.3a

McNerney, K. O., Si Lim, S. J., Ishikawa, K., Dreyzin, A., Vatsayan, A., Chen, J. J., Baggott, C., Prabhu, S., Pacenta, H. L., Philips, C., Rossoff, J., Stefanski, H. E., Talano, J.-A., Moskop, A., Verneris, M., Myers, D., Karras, N. A., Brown, P., Bonifant, C. L., … Schultz, L. M. (2023). HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL. Blood Advances, 7(12), 2758–2771. https://doi.org/10.1182/bloodadvances.2022008893

Damasco-Avila, E., Zelaya Sagastizado, S., Carrillo, M., Blanco, J., Fu, L., Espinoza, D., & Ladas, E. J. (2023). Improving the Quality of the Delivery of Nutritional Care Among Children Undergoing Treatment for Cancer in a Low- and Middle-Income Country. JCO Global Oncology, 9. https://doi.org/10.1200/go.23.00074

Lee, H., Choi, M., Siddiqi, T., Rhodes, J., Wierda, W., Isufi, I., Tuscano, J., Lamanna, N., Subbiah, S., Koff, J., Leslie, L., Goldenberg, A., Chung, G., Breitmeyer, J., Yazji, S., Shih, T., Wang, M., Jamieson, C., & Kipps, T. (2023). Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL). Hematological Oncology, 41(S2), 587–589. Portico. https://doi.org/10.1002/hon.3164_440

de Botton, S., Cluzeau, T., Vigil, C., Cook, R. J., Rousselot, P., Rizzieri, D. A., Liesveld, J. L., Fenaux, P., Braun, T., Banos, A., Jurcic, J. G., Sekeres, M. A., Savona, M. R., Roboz, G. J., Bixby, D., Madigan, K., Volkert, A., Stephens, K., Kang-Fortner, Q., … Stein, E. M. (2023). Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML. Blood Advances, 7(9), 1858–1870. https://doi.org/10.1182/bloodadvances.2022008806

Belsky, J. A., Shoag, J., Harker-Murray, P. D., & Kahn, J. M. (2023). Advances in Pediatric Hodgkin Lymphoma with an Eye on Disparities and Vulnerable Populations. Advances in Oncology, 3(1), 67–76. https://doi.org/10.1016/j.yao.2023.01.016

Putta, S., Young, B. A., Levine, J. E., Reshef, R., Nakamura, R., Strouse, C., Perales, M.-A., Howard, A., Pine, P., Shi, J., Zhang, P., Ho, V. T., & Saber, W. (2023). Prognostic Biomarkers for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Myeloablative Allogeneic Hematopoietic Cell Transplantation: Results from the Blood and Marrow Transplant Clinical Trials Network 1202 Study. Transplantation and Cellular Therapy, 29(3), 166.e1-166.e10. https://doi.org/10.1016/j.jtct.2022.11.024

Wayne, A. S., Huynh, V., Hijiya, N., Rouce, R. H., Brown, P. A., Krueger, J., Kitko, C. L., Ziga, E. D., Hermiston, M. L., Richards, M. K., Baruchel, A., Schuberth, P. C., Rossi, J., Zhou, L., Goyal, L., Jain, R., Vezan, R., Masouleh, B. K., & Lee, D. W. (2022). Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia. Haematologica, 108(3), 747–760. https://doi.org/10.3324/haematol.2022.280678

Etra, A., Capellini, A., Alousi, A., Al Malki, M. M., Choe, H., DeFilipp, Z., Hogan, W. J., Kitko, C. L., Ayuk, F., Baez, J., Gandhi, I., Kasikis, S., Gleich, S., Hexner, E., Hoepting, M., Kapoor, U., Kowalyk, S., Kwon, D., Langston, A., … Levine, J. E. (2023). Effective treatment of low-risk acute GVHD with itacitinib monotherapy. Blood, 141(5), 481–489. https://doi.org/10.1182/blood.2022017442

Kamle, A., Patrikar, S., Chaudhary, P., Malpani, P., & Satwani, P. (2023). Pediatric hematopoietic stem cell transplantation- Experience from a center in central India. Pediatric Hematology Oncology Journal, 8(4), S78. https://doi.org/10.1016/j.phoj.2023.10.198

Stiefel, J., Flower, A. M., Botwinick, M., Ford, M., Foti, A., Gandhi, M., Slovin, J., Smilow, E., Bowers, A., Karpel, H., Schwartz, L. Y., Fraint, E., Gennarini, L. M., Gardner, S. L., Raetz, E. A., Shah, N. C., Chen, J., Krajewski, J., Hijiya, N., … Sulis, M. L. (2022). Antigen Directed Therapy Pre-Transplant Confers Superior Post-Transplant Survival Outcome Compared to Conventional Chemotherapy in Pediatric Patients with Relapsed and Refractory B-ALL. Blood, 140(Supplement 1), 7763–7765. https://doi.org/10.1182/blood-2022-160272

Lee, H. J., Choi, M. Y., Siddiqi, T., Rhodes, J. M., Wierda, W. G., Isufi, I., Tuscano, J. M., Lamanna, N., Subbiah, S., Koff, J. L., Leslie, L., Goldenberg, A., Chung, G. G., Breitmeyer, J. B., Yazji, S., Wang, M., Jamieson, C., & Kipps, T. J. (2022). Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL). Blood, 140(Supplement 1), 566–568. https://doi.org/10.1182/blood-2022-167153

Torres-Diz, M., Thomas-Tikhonenko, A., Reglero, C., Ferrando, A., Falkenstein, C. D., Tasian, S. K., Sehgal, P., Ang, Z., Barash, Y., & Radens, C. (2022). Non-Canonical Exon Usage in Pediatric Leukemia: Implications for Chemoresistance. Blood, 140(Supplement 1), 3264–3265. https://doi.org/10.1182/blood-2022-167006

Chen, Y.-B., Saad, A., Farhan, S. Y., Lekakis, L. J., Schiller, G. J., Yared, J. A., Assal, A., Lee, D. D., Lane, H., Gooley, T. A., & Defilipp, Z. (2022). RGI-2001 Infusion for Prevention of Acute Gvhd after Allogeneic Hematopoietic Cell Transplantation. Blood, 140(Supplement 1), 1877–1878. https://doi.org/10.1182/blood-2022-162512

Fabrizio, V. A., Miller, K., Baggott, C., Prabhu, S., Pacenta, H., Phillips, C. L., Rossoff, J., Stefanski, H. E., Talano, J., Moskop, A., Baumeister, S. H. C., Myers, G. D., Karras, N., Brown, P. A., Qayed, M., Hermiston, M. L., Satwani, P., Krupski, C., Wilcox, R., … Schultz, L. M. (2022). Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults. Blood, 140(Supplement 1), 4661–4663. https://doi.org/10.1182/blood-2022-169603

Capellini, A., Etra, A., Alousi, A. M., Al Malki, M. M., Choe, H., Defilipp, Z., Hogan, W. J., Kitko, C. L., Ayuk, F. A., Baez, J., Gandhi, I., Kasikis, S., Gleich, S., Hexner, E. O., Hoepting, M., Kapoor, U., Kowalyk, S., Kwon, D., Langston, A., … Levine, J. E. (2022). Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy. Blood, 140(Supplement 1), 1867–1869. https://doi.org/10.1182/blood-2022-156000

Genecin, I., Fullwood, D., Moisander-Joyce, H., Padilla, O., Minns, H., Garvin, J., Szalontay, L., Wu, C.-C., Kahn, J., & Gartrell, R. D. (2022). EPID-07. Outcome disparities in children, adolescents and young adults with medulloblastoma: A population-based analysis. Neuro-Oncology, 24(Supplement_1), i48–i48. https://doi.org/10.1093/neuonc/noac079.175

Llanos, A. A. M., Li, J., Tsui, J., Gibbons, J., Pawlish, K., Nwodili, F., Lynch, S., Ragin, C., & Stroup, A. M. (2022). Variation in Cancer Incidence Rates Among Non-Hispanic Black Individuals Disaggregated by Nativity and Birthplace, 2005-2017: A Population-Based Cancer Registry Analysis. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.857548

Wei, K., Liang, Y., Yang, B., Liu, L., Cao, W., Li, T., & Wang, R. (2022). An observational MRI study of methotrexate-treated children with acute lymphoblastic leukemia in remission and subtle cognitive decline. Quantitative Imaging in Medicine and Surgery, 12(4), 2474–2486. https://doi.org/10.21037/qims-21-748

Tran, T. H., Langlois, S., Meloche, C., Caron, M., Saint-Onge, P., Rouette, A., Bataille, A. R., Jimenez-Cortes, C., Sontag, T., Bittencourt, H., Laverdière, C., Lavallée, V.-P., Leclerc, J.-M., Cole, P. D., Gennarini, L. M., Kahn, J. M., Kelly, K. M., Michon, B., Santiago, R., … Sinnett, D. (2022). Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001. Blood Advances, 6(4), 1329–1341. https://doi.org/10.1182/bloodadvances.2021005634

Fabrizio, V. A., Phillips, C. L., Lane, A., Baggott, C., Prabhu, S., Egeler, E., Mavroukakis, S., Pacenta, H., Rossoff, J., Stefanski, H. E., Talano, J.-A., Moskop, A., Margossian, S. P., Verneris, M. R., Myers, G. D., Karras, N. A., Brown, P. A., Qayed, M., Hermiston, M., … Schultz, L. M. (2022). Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report. Blood Advances, 6(2), 600–610. https://doi.org/10.1182/bloodadvances.2021005564

Pennesi, E., Brivio, E., Willemse, M. E., Huitema, A. D. R., Chandra, S., Vijayakumar, A., Van Der Velden, V. H. J., Beverloo, H. B., Durairaj, C., Viqueira, A., Ingrosso, A., Locatelli, F., Motwani, J., Bourquin, J.-P., Bautista Sirvent, F. J., Rizzari, C., Petit, A., Lancaster, D., Metzler, M., … Zwaan, C. M. (2021). A Phase I/II Study of Bosutinib in Pediatric Patients with Resistant/Intolerant or Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia, Study ITCC (Innovative Therapies for Children with Cancer European Consortium) 054 and COG (Children’s Oncology Group Consortium) AAML1921: Results from the Phase I Trial in Resistant/Intolerant Patients. Blood, 138(Supplement 1), 2558–2558. https://doi.org/10.1182/blood-2021-145709

Paolino, J. D., Harris, M. H., Stevenson, K. E., Koch, V., Cole, P. D., Gennarini, L. M., Kahn, J. M., Kelly, K. M., Kirsch, Ii., Michon, B., Place, A. E., Tran, T. H., Welch, J. J. G., & Silverman, L. B. (2021). Performance of Next Generation Sequencing for Minimal Residual Disease Detection for Pediatric Patients with Acute Lymphoblastic Leukemia: Results from the Prospective Clinical Trial DFCI 16-001. Blood, 138(Supplement 1), 3485–3485. https://doi.org/10.1182/blood-2021-152369

Lipsky, A. H., Hill, B. T., Winter, A. M., Jurcic, J. G., Heaney, M. L., Rosenblat, T. L., Chiaramonte, M., Weissbrot, H., & Lamanna, N. (2021). High Rates of Undetectable Minimal Residual Disease Remissions with Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL). Blood, 138(Supplement 1), 1555–1555. https://doi.org/10.1182/blood-2021-150914

Paolino, J. D., Flamand, Y., Stevenson, K. E., Koch, V., Athale, U. H., Cole, P. D., Gennarini, L. M., Kahn, J. M., Kelly, K. M., Laverdiere, C., Leclerc, J.-M., Michon, B., Place, A. E., Supko, J. G., Tran, T. H., Welch, J. J. G., Neuberg, D. S., Sallan, S. E., Silverman, L. B., & Vrooman, L. M. (2021). Impact of Age, Body Surface Area, and Body Mass Index on Pegaspargase Toxicity and Pharmacokinetics: A Report from the DFCI ALL Consortium. Blood, 138(Supplement 1), 3396–3396. https://doi.org/10.1182/blood-2021-151313

Kahn, J. M., Bo-Subait, S., Buchbinder, D. K., Hamilton, B. K., Schoemans, H., Brazauskas, R., Phelan, R., & Satwani, P. (2021). Late Effects after Allogeneic Hematopoietic Cell Transplantation Among Children and Adolescents with Non-Malignant Disorders: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR). Blood, 138(Supplement 1), 412–412. https://doi.org/10.1182/blood-2021-151446

Pemmaraju, N., Kantarjian, H., Sweet, K., Wang, E. S., Lane, A. A., Ali, H., Stein, A. S., Yacoub, A., Rizzieri, D. A., Vasu, S., Gupta, V., Lee, S., Schiller, G. J., Foran, J. M., Taparia, M. S., Rosenblat, T. L., Walter, R. B., Sieminski, D., Anant, M., … Konopleva, M. (2021). Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients with Hematologic Malignancies. Blood, 138(Supplement 1), 2318–2318. https://doi.org/10.1182/blood-2021-145344

Hijiya, N., Kapoor, S., Descamps, L., Bayar, M. A., & Ramscar, N. (2021). Trial in Progress: A Multicenter, Open-Label, Phase Ib/II Study to Determine the Dose and Safety of Asciminib in Pediatric Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated with ≥1 Prior Tyrosine Kinase Inhibitor. Blood, 138(Supplement 1), 2561–2561. https://doi.org/10.1182/blood-2021-151198